# Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

> **NCT02678572** · PHASE3 · COMPLETED · sponsor: **Delcath Systems Inc.** · enrollment: 102 (actual)

## Conditions studied

- Melanoma, Ocular

## Interventions

- **COMBINATION_PRODUCT:** Melphalan/HDS

## Key facts

- **NCT ID:** NCT02678572
- **Lead sponsor:** Delcath Systems Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-08-15
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678572, "Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02678572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*